DBV Technologies (DBVT) Asset Writedowns and Impairment (2024 - 2026)
DBV Technologies (DBVT) reported Asset Writedowns and Impairment of $3.0 million for Q1 2026, down 30.23% year-over-year from $4.3 million in Q1 2025, and up 40.78% on a QoQ basis from $2.1 million in Q4 2025.
DBV Technologies (DBVT) has 3 years of Asset Writedowns and Impairment data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 30.23% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (up 235.58% YoY) and the FY2025 annual result came in at $16.1 million, up 1057.2% from the prior year.
- Asset Writedowns and Impairment rose to $3.0 million in Q1 2026 per DBVT's latest filing, from $2.1 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $6.0 million in Q2 2025 and bottomed at $99000.0 in Q3 2024.
- The 3-year median for Asset Writedowns and Impairment is $3.0 million (2026), against an average of $2.9 million.
- The widest annual swing landed in 2025, when Asset Writedowns and Impairment jumped 3617.17%; it then tumbled 30.23% in 2026.
- Tracing DBVT's Asset Writedowns and Impairment over 3 years: stood at $99000.0 in 2024, then jumped by 2052.53% to $2.1 million in 2025, then surged by 40.78% to $3.0 million in 2026.
- Per Business Quant, the three latest DBVT Asset Writedowns and Impairment figures stand at $3.0 million (Q1 2026), $2.1 million (Q4 2025), and $3.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 2.13 Mn |
| Dec 31, 2025 | 2.13 Mn |
| Sep 30, 2025 | 3.68 Mn |
| Sep 30, 2025 | 3.68 Mn |
| Jun 30, 2025 | 5.95 Mn |
| Jun 30, 2025 | 5.95 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Sep 30, 2024 | 99,000.00 |
| Sep 30, 2024 | 99,000.00 |
| Mar 31, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.29 Mn |